AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine the time to progression of the combination
of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not
received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study
is to determine the dose of study drug that can be given with docetaxel administered on an
every 3 week schedule.